A. Lévy

First case of chromoblastomycosis from Bangladesh

Chromoblastomycosis is a rare and chronic cutaneous and subcutaneous infection caused by black fungi and mostly reported in tropical and subtropical areas. Here we report the first case of chromoblastomycosis from Bangladesh. Molecular biology permitted to identify Fonsecaea nubica, and the patient responded well to antifungal treatment alone.

Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature

An 83-year-old patient developed erosions and a blister of the gingival mucous membrane, 6 months after discontinuation of the anti-programmed death-1 (anti PD-1) pembrolizumab therapy administered for 10 months for a metastatic melanoma. A diagnosis of mild mucous membrane pemphigoid (MMP) was made. Complete remission of MMP was rapidly obtained with minimal therapy (doxycycline). MMP remained in complete remission after a 3-month follow-up since discontinuation of the doxycycline therapy and no evidence of relapse of the melanoma was observed after a 14-month follow-up since discontinuation of the pembrolizumab therapy. The widespread use of anti PD-1 and anti-programmed death-ligand-1 (PD-L1) in several malignancies reveals new adverse events. MMP describes a group of chronic, inflammatory, mucous membrane-predominant, subepithelial auto-immune blistering diseases. It is clinically distinct from bullous pemphigoid another autoimmune blistering disease but shares some immunological similarities with it. Twenty-nine cases of bullous pemphigoid associated with anti PD-1/PD-L1 have been reported in the literature and one of MMP. Here, we described the case of a MMP developed after pembrolizumab and discussed the accountability of anti PD-1/PD-L1 in our case and the previous reported bullous pemphigoid and MMP cases using the Begaud system scoring.

A case of a focal oedematous reaction induced by rituximab overlying lupus erythematosus tumidus

EJD, vol. 27, n◦ 5, September-October 2017 was unknown in these responding patients, our second case provides evidence, for the first time, that CMML cells in the bone marrow, skin, and mucosa were derived from the same TET2-mutated clone, which was more sensitive to AZA than bone marrow cells. The altered methylation pattern, secondary to TET2 mutations, may have contributed to the response to HMA; while surgery and radiotherapy likely played the most important role in obtaining complete eradication of the labial tumour, the skin lesions regressed only after hypomethylation. Notably, the haematological remission was not associated with disappearance of TET2 mutations in the bone marrow, suggesting a limited effect of AZA at the molecular level. Finally, the beneficial effect of AZA was demonstrated by the regression of cutaneous lesions in neoplastic disorders other than CMML, as in blastic plasmacytoid dendritic cell neoplasms [9], squamous cell carcinomas, and keratoacanthomas [10].

Corrigendum to “First case of chromoblastomycosis from Bangladesh” [Med. Mycol. Case Rep. 10 (2015) 1–3]

[This corrects the article DOI: 10.1016/j.mmcr.2015.08.001.].